Memantine Inhibitor

Memantine, an amantadine derivative with some dopaminergic effects, has been proposed as an antiparkinson agent and has may be used to treat moderate to severe Alzheimer's disease. It acts on the glutamatergic system by blockingnMDA receptors.

Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, Chou KR. treatment,effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One. 2017 Aug 21;12(8):e0183586. doi: 10.1371/journal.pone.0183586. eCollection 2017. PubMed PMID: 28827830; PubMed Central PMCID: PMC5565113.
Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment,of moderate-to-severe Alzheimer's disease. Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. eCollection 2016. Review. PubMed PMID: 27757016; PubMed Central PMCID: PMC5055113.
Greig SL. Memantine ER/Donepezil: A Review in Alzheimer's Disease. CNS Drugs. 2015 Nov;29(11):963-70. doi: 10.1007/s40263-015-0287-2. Review. PubMed PMID: 26519339.
Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 2015. Review. PubMed PMID: 25860130; PubMed Central PMCID: PMC4393306.

Small volumes of Memantine, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756607 is an inhibitor targeting Memantine.